Lázas, neutropeniás gyermekek kezelése meropenemmel.

Translated title of the contribution: Meropenem therapy in children with febrile neutropenia

J. Müller, Gábor Kovács, M. Garami, Marianne Schmidt, G. Fekete

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

OBJECTIVES: Infectious complications are the major causes of morbidity and mortality in children receiving chemotherapy for malignant diseases. Granulocytopenia carries the risk of bacterial infection, and also, if prolonged, of fungal infection. The aim of this study was to evaluate the clinical effectiveness of meropenem in immunocompromised children in association with isolated bacteria from blood cultures and clinical background. METHODS: Retrospective study of all febrile episodes when meropenem was used in neutropenic children between January 1998 and December 2002 in the haemato-oncological units of the authors hospital. During the study period meropenem was used in 87 febrile events diagnosed in 55 patients (mean age 10 years 5 months), and 328 bacterial cultures were performed. Blood samples were taken from each patient with granulocytopenia (<0.5 G/l) and fever (> or = 38 degrees C), prior to the start of any antibiotic therapy. For the microbiological process Bactec 9050 (Becton Dickinson) blood culture systems were used. RESULTS: Microorganisms were detected and identified in 64 (19.5%) from the 328 hemocultures. There was a predominance of Gram-positive strains, 67% (43/64)--the most common bacteria being coagulase negative Staphylococcus (cnS). From the 87 periods in 43 cases (49.4%) the infection was documented microbiologically. In 16 additional cases the infection was proven clinically (based on the clinical course, laboratory and radiologic results) and 32.2% (28/87) of the febrile neutropenic episodes were considered to be fever of unknown origin. Meropenem was used in a mean dose of 60.8 (30-120) mg/kg/die, for 9.3 (2-24) days. The success rate of the meropenem therapy -excluding the proven fungal (n = 13) or cnS (n = 15) infections-was 72.9%. No severe side effects occurred in any regimens. CONCLUSION: The results demonstrate that meropenem is effective and well-tolerated when used for the treatment of feverish neutropenic cancer children.

Original languageHungarian
Pages (from-to)2115-2120
Number of pages6
JournalOrvosi Hetilap
Volume144
Issue number43
Publication statusPublished - Oct 26 2003

Fingerprint

meropenem
Febrile Neutropenia
Agranulocytosis
Fever
Coagulase
Staphylococcus
Microbiological Phenomena
Therapeutics
Infection
Bacteria
Fever of Unknown Origin
Child Mortality
Hospital Units
Mycoses
Bacterial Infections
Retrospective Studies
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lázas, neutropeniás gyermekek kezelése meropenemmel. / Müller, J.; Kovács, Gábor; Garami, M.; Schmidt, Marianne; Fekete, G.

In: Orvosi Hetilap, Vol. 144, No. 43, 26.10.2003, p. 2115-2120.

Research output: Contribution to journalArticle

Müller, J, Kovács, G, Garami, M, Schmidt, M & Fekete, G 2003, 'Lázas, neutropeniás gyermekek kezelése meropenemmel.', Orvosi Hetilap, vol. 144, no. 43, pp. 2115-2120.
Müller, J. ; Kovács, Gábor ; Garami, M. ; Schmidt, Marianne ; Fekete, G. / Lázas, neutropeniás gyermekek kezelése meropenemmel. In: Orvosi Hetilap. 2003 ; Vol. 144, No. 43. pp. 2115-2120.
@article{0731962c46c347cba8a33a89528603ab,
title = "L{\'a}zas, neutropeni{\'a}s gyermekek kezel{\'e}se meropenemmel.",
abstract = "OBJECTIVES: Infectious complications are the major causes of morbidity and mortality in children receiving chemotherapy for malignant diseases. Granulocytopenia carries the risk of bacterial infection, and also, if prolonged, of fungal infection. The aim of this study was to evaluate the clinical effectiveness of meropenem in immunocompromised children in association with isolated bacteria from blood cultures and clinical background. METHODS: Retrospective study of all febrile episodes when meropenem was used in neutropenic children between January 1998 and December 2002 in the haemato-oncological units of the authors hospital. During the study period meropenem was used in 87 febrile events diagnosed in 55 patients (mean age 10 years 5 months), and 328 bacterial cultures were performed. Blood samples were taken from each patient with granulocytopenia (<0.5 G/l) and fever (> or = 38 degrees C), prior to the start of any antibiotic therapy. For the microbiological process Bactec 9050 (Becton Dickinson) blood culture systems were used. RESULTS: Microorganisms were detected and identified in 64 (19.5{\%}) from the 328 hemocultures. There was a predominance of Gram-positive strains, 67{\%} (43/64)--the most common bacteria being coagulase negative Staphylococcus (cnS). From the 87 periods in 43 cases (49.4{\%}) the infection was documented microbiologically. In 16 additional cases the infection was proven clinically (based on the clinical course, laboratory and radiologic results) and 32.2{\%} (28/87) of the febrile neutropenic episodes were considered to be fever of unknown origin. Meropenem was used in a mean dose of 60.8 (30-120) mg/kg/die, for 9.3 (2-24) days. The success rate of the meropenem therapy -excluding the proven fungal (n = 13) or cnS (n = 15) infections-was 72.9{\%}. No severe side effects occurred in any regimens. CONCLUSION: The results demonstrate that meropenem is effective and well-tolerated when used for the treatment of feverish neutropenic cancer children.",
author = "J. M{\"u}ller and G{\'a}bor Kov{\'a}cs and M. Garami and Marianne Schmidt and G. Fekete",
year = "2003",
month = "10",
day = "26",
language = "Hungarian",
volume = "144",
pages = "2115--2120",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "43",

}

TY - JOUR

T1 - Lázas, neutropeniás gyermekek kezelése meropenemmel.

AU - Müller, J.

AU - Kovács, Gábor

AU - Garami, M.

AU - Schmidt, Marianne

AU - Fekete, G.

PY - 2003/10/26

Y1 - 2003/10/26

N2 - OBJECTIVES: Infectious complications are the major causes of morbidity and mortality in children receiving chemotherapy for malignant diseases. Granulocytopenia carries the risk of bacterial infection, and also, if prolonged, of fungal infection. The aim of this study was to evaluate the clinical effectiveness of meropenem in immunocompromised children in association with isolated bacteria from blood cultures and clinical background. METHODS: Retrospective study of all febrile episodes when meropenem was used in neutropenic children between January 1998 and December 2002 in the haemato-oncological units of the authors hospital. During the study period meropenem was used in 87 febrile events diagnosed in 55 patients (mean age 10 years 5 months), and 328 bacterial cultures were performed. Blood samples were taken from each patient with granulocytopenia (<0.5 G/l) and fever (> or = 38 degrees C), prior to the start of any antibiotic therapy. For the microbiological process Bactec 9050 (Becton Dickinson) blood culture systems were used. RESULTS: Microorganisms were detected and identified in 64 (19.5%) from the 328 hemocultures. There was a predominance of Gram-positive strains, 67% (43/64)--the most common bacteria being coagulase negative Staphylococcus (cnS). From the 87 periods in 43 cases (49.4%) the infection was documented microbiologically. In 16 additional cases the infection was proven clinically (based on the clinical course, laboratory and radiologic results) and 32.2% (28/87) of the febrile neutropenic episodes were considered to be fever of unknown origin. Meropenem was used in a mean dose of 60.8 (30-120) mg/kg/die, for 9.3 (2-24) days. The success rate of the meropenem therapy -excluding the proven fungal (n = 13) or cnS (n = 15) infections-was 72.9%. No severe side effects occurred in any regimens. CONCLUSION: The results demonstrate that meropenem is effective and well-tolerated when used for the treatment of feverish neutropenic cancer children.

AB - OBJECTIVES: Infectious complications are the major causes of morbidity and mortality in children receiving chemotherapy for malignant diseases. Granulocytopenia carries the risk of bacterial infection, and also, if prolonged, of fungal infection. The aim of this study was to evaluate the clinical effectiveness of meropenem in immunocompromised children in association with isolated bacteria from blood cultures and clinical background. METHODS: Retrospective study of all febrile episodes when meropenem was used in neutropenic children between January 1998 and December 2002 in the haemato-oncological units of the authors hospital. During the study period meropenem was used in 87 febrile events diagnosed in 55 patients (mean age 10 years 5 months), and 328 bacterial cultures were performed. Blood samples were taken from each patient with granulocytopenia (<0.5 G/l) and fever (> or = 38 degrees C), prior to the start of any antibiotic therapy. For the microbiological process Bactec 9050 (Becton Dickinson) blood culture systems were used. RESULTS: Microorganisms were detected and identified in 64 (19.5%) from the 328 hemocultures. There was a predominance of Gram-positive strains, 67% (43/64)--the most common bacteria being coagulase negative Staphylococcus (cnS). From the 87 periods in 43 cases (49.4%) the infection was documented microbiologically. In 16 additional cases the infection was proven clinically (based on the clinical course, laboratory and radiologic results) and 32.2% (28/87) of the febrile neutropenic episodes were considered to be fever of unknown origin. Meropenem was used in a mean dose of 60.8 (30-120) mg/kg/die, for 9.3 (2-24) days. The success rate of the meropenem therapy -excluding the proven fungal (n = 13) or cnS (n = 15) infections-was 72.9%. No severe side effects occurred in any regimens. CONCLUSION: The results demonstrate that meropenem is effective and well-tolerated when used for the treatment of feverish neutropenic cancer children.

UR - http://www.scopus.com/inward/record.url?scp=17644436253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644436253&partnerID=8YFLogxK

M3 - Article

VL - 144

SP - 2115

EP - 2120

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 43

ER -